Protalix is a publicly traded biotechnology company
(AMEX: PLX),
that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.
About Us
Corporate Profile
Market Needs
Protalix Advantage
Management Team
Scientific Advisory Board
Press Room
Careers
Technology
ProCellex Overview
Platform Technology
Protein Production
Product Development
Glucocerebrosidase
Pipeline Products
Partnerships
Investor Relations
Corporate Strategy
Management Team
Board of Directors
Stock Information
Corporate Governance
Filings
Press Releases
FAQs
Contact Us
Patients
Investor Relations
LATEST NEWS
<GO TO PRESS ROOM>
04/08/08
Protalix BioTherapeutics Receives Research Grant from the Office of the Chief Scientist of Israel's Ministry of Industry and Trade
01/14/08
Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
PROTALIX BIOTHERAPEUTICS
2 Snunit St., Science Park,
POB 455, Karmiel 20100, Israel.
T: +972-4-9028100
F: +972-4-988-9489
E:
info@protalix.com
patient-info@protalix.com
© 2008 Protalix Biotherapeutics. All Rights Reserved.